Kornimate/medical-research-clean huggingface dataset:
hyperkalaemia prevalence, recurrence and treatment in haemodialysis

Conditions: Hyperkalemia; Hemodialysis; Water-Electrolyte Imbalance

Summary: the objective of this study is to evaluate the prevalence and recurrence of hyperkalaemia (hk) in chinese hd patients and to understand the treatment pattern of hk in china.

this is a prospective, cohort study. this study will include approximate 600 end stage renal disease (esrd) patients receiving haemodialysis (hd) treatment twice a week or thrice a week. the assessments at enrolment and in follow-up are summarized as follow: enrolment - patients will be in long interdialytic interval (lidi) at enrolment (v1). demographic characteristics, medical history, etiology of esrd, concomitant medications, dialysis vintage, an electrocardiogram (ecg), a pre-dialysis serum potassium measurement and a post- dialysis serum potassium measurement, blood routine, blood gas analysis and other blood biochemistry measurements, etc., will be obtained. follow-up - potassium measurements, including pre-dialysis potassium measurements at lidi once every month (v3-v8), pre-dialysis potassium at sidi during the first week (v2) for patients in hd thrice a week specifically, will be obtained. concomitant medications, blood routine, blood gas analysis and other blood biochemistry measurements, etc., will be obtained

Eligibility criteria:
inclusion criteria: 1. patient aged ≥ 18 years at the time of signing the informed consent. 2. patients with esrd and on haemodialysis (hd) 3. the hd treatment frequency is ≥2 sessions per week 4. capable of giving signed informed consent exclusion criteria: 1. acute kidney injury 2. expected to receive renal transplantation within 6 months 3. intracranial haemorrhage or elevated intracranial pressure within one month before enrolment 4. shock that cannot be corrected by drugs within one month before enrolment 5. failure to establish vascular access 6. has been receiving peritoneal dialysis 7. not suitable for this study judged by investigators

Keywords: hyperkalemia
efficacy study of chg regimen vs decitabine to treat higher-risk mds

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to compare the efficacy of chg regimen (low-dose cytarabine, homoharringtonine with g-csf priming) to decitabine in the treatment of higher-risk myelodysplastic syndromes(mds).

patients with higher-risk myelodysplastic syndrome (mds) have a survival rate of 0.4 to 1.2 years as well as a high risk of their disease progressing to acute myeloid leukemia (aml). the only treatment with a curative potential is allogeneic stem cell transplantation. however, in the majority of patients, this treatment is not applicable, mainly due to the age of the recipients and comorbid conditions. low-dose chemotherapy chg regimen (low-dose cytarabine, homoharringtonine with g-csf priming)has been used to treat higher-risk mds in china and achieve high response rate. hypomethylating agents 5-aza-2'-deoxycytidine (decitabine) is nucleoside analogs that covalently bind to the dna methyltransferases, irreversibly inhibiting their function, leading to the progressive loss of methylation and reversal of gene silencing. the purpose of this study is to compare the efficacy and safety of chg regimen to decitabine in higher-risk mds.

Eligibility criteria:
inclusion criteria: * age rang from 16 to 80 years; * diagnosis of higher-risk mds (with≥ 5% blast in bone marrow); * a performance status of 0-3 according to the eastern cooperative oncology group (ecog); * no evidence of severe concurrent cardiac, pulmonary, neurologic, or metabolic diseases; * adequate hepatic (serum bilirubin level \<2×upper normal limit) and renal (serum creatinine \<2×upper normal limit) function tests. exclusion criteria: * female with pregnancy; * a performance of 4-5 according to ecog score; * hiv positive; * uncontrolled severe fungal infection or tuberculosis; * with other progressive malignant diseases.

Keywords: myelodysplastic syndromes decitabine homoharringtonine cytarabine g-csf
ct evaluating the efficacy of pre-incisional local analgesia with ropivacaine + dexamethasone in pain management after tonsillectomy

Conditions: Tonsillectomy

Summary: this study is a randomized, controlled, double-blind clinical trial to evaluate the effect of local infiltration of ropivacaine and dexamethasone, alone or in association, in the reduction of pain and the need for supplementary analgesia, after tonsillectomy, in the immediate and late postoperative period, in individuals aged 18 to 65 years. the present clinical trial will include 4 study groups, each with different content of infiltration into the amygdaline locus. one group will have ropivacaine in the infiltration, the other will have dexamethasone and another the association of these two drugs. in order to better understand the effectiveness of these drugs, there will also be a control group, in which saline solution will be infiltrated. approximately 104 individuals, aged 18 to 65 years, proposed for tonsillectomy will be included in the study, i.e., 26 subjects in each study group. postoperative pain will be characterized by self-assessment through the visual analog scale (vas, 100mm) at various moments of the study, namely in the preoperative consultation, in the pre-anesthetic consultation, at hospital admission and in the postoperative period until the 15th day after the surgery. the aim of this study is not to eliminate intra and postoperative analgesia, but rather account for the need for analgesia depending on the different infiltration content peramygdalin. for this, in the postoperative period, a careful pain monitoring, having first-line analgesic and rescue medication for use immediate response in the face of minimal pain assessed by validated pain scales. it is intended, therefore, to record which analgesic drugs and in what doses were necessary.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-ii; * surgical proposal of tonsillectomy; * tonsillectomy performed by the cold shedding technique; * history of recurrent tonsillitis, caseous tonsillitis and / or peritonsillar abscess; exclusion criteria: * use of chronic analgesic medication; * asa iii-iv; * coagulation disorders, such as von willebrand disease or diagnosis of other platelet disorders, haemophilia a and b, or diseases that may develop with hemostatic dysfunction; * intolerance or allergy to any of the drugs used in the study; * suspicious or confirmed diagnosis of neoplastic disease; * fever or acute respiratory tract infection in the last 3 weeks;

Keywords: tonsillectomy pain management
effect of patient navigation on colonoscopy completion screening rate for colorectal cancer.

Conditions: Colorectal Cancer Screening; Patient Navigation

Summary: the goal of this randomized controlled trial is to evaluate the effectiveness of patient navigation on colonoscopy completion rates in a population screened for colorectal cancer. the main question\[s\] it aims to answer are: are colonoscopy completion rates in colorectal cancer screening increased in navigated (intervention arm) compared with non-navigated (control arm) participants? is mental well-being, as measured by hads and ghq12 scores, better in the intervention arm compared with the control arm? participants in the intervention arm will receive: * standard clinic instructions for the colonoscopy * phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure * a webpage qr code consist of information on visual image on colonoscopy preparation and procedures, layout and map guidance to navigate in the hospital * a direct line for phone calls to patient navigators for further guidance on overcoming barriers participants in the control arm will only receive: * standard clinic instructions for the colonoscopy * one phone call from the patient navigator to discuss the colonoscopy procedure


Eligibility criteria:
inclusion criteria: * average risk for crc * more than 50 years of age * capacity for informed consent * ifobt positive exclusion criteria: * moderate or high risk crc * previous crc screening * symptomatic

Keywords: rct colorectal cancer screening patient navigation malaysia depression anxiety hads ghq12
drum-assisted therapy for native americans

Conditions: Substance Use Disorders

Summary: drum-assisted recovery therapy for native americans (dartna) is an r-21 nih/nccam-funded study aimed to complete the development and pilot a new substance abuse treatment protocol utilizing drumming for american indians/alaska natives with substance use disorders. the study includes activities to complete the protocol, followed by a randomized-controlled clinical trial.

during year 1, this study consists of a series of focus groups conducted among american indians/alaska natives with substance use disorders, providers serving ai/ans with substance use disorders, and a community advisory board. these focus groups are conducted in order to obtain feedback with regard to the initial dartna treatment protocol. these focus groups are then followed by a pretest of dartna among 10 ai/ans with substance use disorders followed by a series of focus groups to finalize the development of dartna. during year 2, a randomized controlled will be conducted among 30 ai/ans receiving the dartna treatment protocol vs. 30 ai/ans receiving treatment-as-usual at united american indian involvement, inc. in los angeles.

Eligibility criteria:
inclusion criteria: * meeting diagnostic and statistical manual of mental disorders (dsm-iv-tr; american psychiatric association, 2000) criteria of current alcohol or drug abuse or dependence * self-identifying as at least ¼ american indian/alaska native heritage * seeking treatment for alcohol or drug abuse * being at least 18 years old. clients will be assessed for suitability for outpatient treatment. exclusion criteria: * have a psychiatric conditions that is not suitable for outpatient treatment (e.g., if they require inpatient rehabilitation treatment, have significant psychiatric disorders, require medical detoxification, or have significant medical problems) * have a current suicidal ideation/plan as assessed by the asi or bsi * are mandated by the court to obtain treatment for substance abuse where such mandate requires the results of urine toxicology tests to be reported to the court * expectation that the participant will fail to complete the study protocol due to probable incarceration or relocation from the clinic area.

Keywords: american indians native americans substance abuse culture
micronutrients in management of symptomatic oral lichen planus

Conditions: Oral Lichen Planus

Summary: treatment of oral lichen planus is challenging. diverse therapeutic modalities have been suggested, but a permanent cure is not yet available. in some olp patients, topical corticosteroid alone is not sufficiently enough, thus it may require a supplementation to augment its effect. micronutrients are gaining more attention as therapeutic modalities in immunologic disorders. researchers are recommended to conduct further clinical studies are to assess the role of these elements in management of olp (gholizadeh \& sheykhbahaei, 2020). among the less visited micronutrients are zinc and vitamin d. this trial will assess their role in management of olp.

the enrolled patients will be divided randomly into three groups. one group will receive topical corticosteroid (kenacort a orabase: triamcinolone acetonide 0.1% adhesive paste - dermapharm) four times daily, the second group will receive topical corticosteroid (kenacort a orabase: triamcinolone acetonide 0.1% adhesive paste - dermapharm) four times daily with systemic zinc (octozinc: zinc sulphate heptahydrate 25 mg tablets - october pharma) twice daily and the third group will receive topical corticosteroid (kenacort a orabase: triamcinolone acetonide 0.1% adhesive paste - dermapharm) four times daily with systemic vitamin d (cholecalciferol: vitamin d3 15 ml oral solution - medical union pharmaceuticals) once daily. the patients will be recalled weekly for eight weeks. for every four weeks of topical corticosteroid application, topical oral antifungal (daktarin 2% oral gel - miconazole) will be prescribed, four times daily for one week, to all the patients in the trial, to avoid secondary infection with oral candidiasis. the patients will be asked to prohibit the use of any topical or systemic medication during the trial.

Eligibility criteria:
inclusion criteria: * patients suffering from erosive or atrophic olp * patients free from any visible oral lesions other than olp. * patients who agreed to take the supplied interventions. * patient who will agree to participate in the study. * patients who will accept to sign the informed consent. exclusion criteria: * patients suffering from any systemic disease. * treatment with any systemic treatment such as systemic steroids, other immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks. * treatment with any oral topical medications for at least four weeks prior to the study. * pregnant and lactating mothers.

Keywords: micronutrients topical corticosteroids
long-term sedation with remimazolam besylate in critically ill patients

Conditions: Light Sedation; Mechanical Ventilation

Summary: a randomized non-inferior trial comparing remimazolam besylate with propofol for long-term sedation during invasive mechanical ventilation in critically ill patients


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 80 years; * intubated and mechanically ventilated ≤96 hours before enrollment； * expected to require continuous invasive ventilation and sedation ≥24 hours; * requirement for light to moderate sedation (a rass score of -3 to 0) exclusion criteria: * body mass index (bmi) \ 30 kg/m2; * allergy or unsuitabilty to any composition of study drugs or remifentanil; * living expectancy less than 48 hours； * possible surgey in the operating room in 24 hours； * myasthenia gravis; * serious hepatic dysfunction (ctp 10-15); * chronic kidney disease with glomerular filtration rate (gfr) \< 29 ml/min/1.73m2; * systolic blood pressure less than 90 mm hg after appropriate intravenous volume replacement and continuous infusions of 2 vasopressors; * acute severe neurological disorder and any other condition interfering with rass assessment; * pregnancy or lactation; * unstable angina or acute myocardial infarction; * left ventricular ejection fraction less than 30%; * heart rate less than 50 beats/min; * grade 2 , second degree or third degree atrioventricular block in the absence of a pacemaker; * abuse of controlled substances or alcohol; * other conditions deemed unsuitable to be included;
treatment of burning mouth syndrome with integration of traditional chinese medicine and western medicine

Conditions: Burning Mouth Syndrome

Summary: this study is an open-label randomized controlled trial of the efficacy of the integration of traditional chinese medicine (tcm) and western medicine based on tcm syndrome differentiation. the hypothesis is (1) tcm model can identify the primary and secondary type burning mouth syndrome (bms); (2) tcm model can identify bms after treatment with western medicine; (3) there is a positive effect of tcm in treating bms.

bms patients will be classified into the primary type and secondary type according to the patients' clinical histories and laboratory examinations. the secondary bms only includes nutritional deficiency, such as vitamin b12, folate, iron, zinc. at first, the primary bms patients are treated with 0.5\~1 mg clonazepam every day before sleep for 8 weeks. the secondary bms patients are treated with vitamin b12, folate, iron and zinc according to the patient's nutritional deficiency status. patients with no improvement or little improvement after the first stage of western medicine management will be arranged to receive traditional chinese medicine (tcm) therapy. all patients will receive the tcm model, including tcm doctor, automatic tongue diagnostic system (atds), and body constitutional questionnaire (bcq), evaluations. the results of this study are expected to understand whether adjuvant tcm treatment of bms can improve treatment efficacy. the investigators will understand whether the constitution pattern may be a predictive indicator of efficacy for western bms. the investigators will find a diagnostic indicator for the tcm model and apply it to the assessment of the prognosis of bms patients.

Eligibility criteria:
inclusion criteria: 1. participants who signed the informed consent 2. the clinical diagnosis was primary or secondary type bms patient 3. ≥ 20-year-old 4. female 5. willing to take traditional chinese medicine exclusion criteria: 1. history of an angiotensin-converting enzyme inhibitor (acei) taking 2. autoimmune disease 3. poor kidney function 4. unwilling to take traditional chinese medicine 5. male 6. participants who have been treated with tcm or acupuncture within a month 7. participants who have been treated with medicine for burning mouth syndrome

Keywords: burning mouth syndrome traditional chinese medicine automatic tongue diagnosis system body constitution questionnaire
switching from morphine to oral methadone plus acetaminophen in the treatment of cancer pain

Conditions: Cancer; Pain; Palliative Care

Summary: the purpose of this study is to determine whether oral methadone plus acetaminophen can substitute morphine in the treatment of cancer pain.

opioids are the mainstay of moderate-to-severe cancer pain management. although morphine is the most commonly used, methadone has some advantages such as higher potency, lower cost and longer administration intervals. to minimize the time necessary to achieve the equianalgesic effect after a switching from morphine to methadone, acetaminophen was added in the treatment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cancer pain * regular use of oral morphine exclusion criteria: * use of acetaminophen in the last 48 hours * renal or hepatic failure

Keywords: cancer pain methadone morphine acetaminophen palliative care
electromagnetic stimulation of the phrenic nerve of intubated patients with obesity

Conditions: General Anaesthesia; Muscle Weakness

Summary: ventilator-induced diaphragmatic dysfunction is a common issue in critically ill patients. muscle stimulation has shown to have beneficial effects in muscle groups on the extremities. a non-invasive way to stimulate the diaphragm would be the electromagnetic stimulation but it is currently unclear if that is feasible. in this proof-of-concept trial the primary aim is to show that it is possible to induce a diaphragmatic contraction leading to an inspiration with a sufficient tidal volume via an external electromagnetic stimulation of the phrenic nerve in obese patients.

during the time of first spontaneous breathing trial 60% of mechanically ventilated patients present with diaphragmatic weakness or also know as ventilator-induced diaphragmatic dysfunction (vidd). the damage to the diaphragm in terms of muscle atrophy has been shown as early as 12 hours after initiation of mechanical ventilation. recently, a correlation between diaphragmatic atrophy and mortality could be established. induction of diaphragmatic contractions via stimulation of the phrenic nerve would be a possible method to prevent or treat vidd. a possible modality would be the non-invasive electromagnetic stimulation but feasibility has not been established. in this proof-of-concept trial the primary aim is to show that it is possible to induce a diaphragmatic contraction leading to an inspiration with a sufficient tidal volume via an external electromagnetic stimulation of the phrenic nerve in obese patients

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * american society of anaesthesiologists classification i or ii * planned anesthesia with intubation * adipositas grade ii-iii exclusion criteria: * chronic lung disease * preexisting diaphragmatic weakness * neurologic disease with known motor weakness * paralysis of the phrenic nerve * contraindication for any movement in the cervical vertebrae * conditions that limit the movement of the diaphragm e.g. ascites, increased intraabdominal pressure. * inability to communicate in the official language * infections, lesions or stricture in the neck area * implanted cardiac devices e.g. pace maker, defibrillator, event recorder * implanted medical pumps e.g. left ventricular assist device * metal implants in the upper body * preganancy

Keywords: vidd icuaw muscle weakness
uphi: wireless body area network core technology

Conditions: Asystole; Sinus Bradycardia; Sinus Tachycardia; Sinus Arrhythmia; Atril Fibrillation

Summary: the application scenario is shown in the figure below: the user utilizes an ecg-based wireless sensor (wiboc chipset), and transmit those signals to a mobile-phone device that has an embedded expert system integrated. with the aid of 3g system, a remote healthcare monitoring center receives those uploaded signals and stores into the application server. according to the events from this server, the people on service responses to the emergency and takes the corresponding process.


Eligibility criteria:
inclusion criteria: * emergency patient with chest pain. * emergency patients were implementation of 12-lead ekg during observation. * out-patient services of cardiology with arrhythmia history. * adults over 20 years old. exclusion criteria: * the patient required the intervention of resuscitation and cardiac massage. * chest trauma * on pacemaker
comparison of efficacy and safety between ticagrelor and clopidogrel in chinese

Conditions: Acute Coronary Syndrome

Summary: this is a prospective, single-center study to assess the long- and short-term outcomes of ticagrelor vs clopidogrel in chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. patients will undergo face-to-face interviews, phone calls, or/and chart reviews at 7 days, 1 month, 6 months and 12 months. when 4500 patients have completed the follow-up, an interim analysis will be performed.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older; 2. diagnosed as acute coronary syndrome; 3. underwent successful percutaneous coronary intervention. exclusion criteria: 1. participate in any drug clinical trials within 3 months; 2. patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years; 3. serious neurological disease (alzheimer's disease, parkinson syndrome, progressive lower limbs or deaf patients); 4. previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix); 5. patients refused to comply with the requirements of this study to complete the research work.

Keywords: ticagrelor clopidogrel acute coronary syndrome percutaneous coronary intervention